KEAP1 and non-small cell lung carcinoma: Among the 104 patients (KRAS-mutant NSCLC is mainly adenocarcinoma, accounting for 95.2%) who were assessed for co-occurring genomic alterations, efficacy was seen in the subgroups with mutated STK11, KEAP1, or TP53.